Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
Pre-Market: $185.50 -0.18 (-0.10%) 9:26 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
Pre-Market: $185.50 -0.18 (-0.10%) 9:26 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Top Ranked Momentum Stocks to Buy for August 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 12th.
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Biotech ETFs in Focus on Impressive Q2 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
Top Ranked Momentum Stocks to Buy for August 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 2nd.
Top Ranked Momentum Stocks to Buy for July 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 31st.
3 Reasons Growth Investors Will Love Biogen (BIIB)
by Zacks Equity Research
Biogen (BIIB) could produce exceptional returns because of its solid growth attributes.
Zacks.com featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman
by Zacks Equity Research
Zacks.com featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
Top 5 ROE Stocks to Buy as Dovish Fed Stance Spurs Volatility
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
Top Analyst Reports for Texas Instruments, Blackstone & Northrop Grumman
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Blackstone (BX) and Northrop Grumman (NOC).
Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
by Zacks Equity Research
Key highlights of the past week include earnings update, collaborations and other pipeline news.
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
by Zacks Equity Research
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the second quarter. It lifts sales and earnings expectations for the year. Shares rise in pre-market trading
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen & Novartis' Alzheimer Studies End in Another Failure
by Zacks Equity Research
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
Will Patent Woes Boost Pharma Stock Megamergers Further?
by Nilanjan Banerjee
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Top Analyst Reports for Boeing, 3M & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), 3M (MMM) and U.S. Bancorp (USB).
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Atara Reports Initial Data for Multiple Sclerosis Candidate
by Zacks Equity Research
Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.
5 ROE Stocks to Buy as Trade Talks Resume Ahead of G20 Summit
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB)
by Zacks Equity Research
Biogen (BIIB) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon